Navigation Links
Osteotech Engages BioHorizons as Exclusive Distributor to International Dental Market
Date:4/30/2008

EATONTOWN, N.J., April 30 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic solutions for regenerative medicine, announced today that it has signed an exclusive distribution agreement with BioHorizons, Inc., effective as of April 1, 2008, under which BioHorizons will market Osteotech's bone regeneration products to the dental market in 29 countries in Europe, the Middle East, Latin America and Asia. Osteotech and BioHorizons previously entered into an agreement for BioHorizons to distribute Osteotech's products to the United States dental market in 2000.

Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer, commented, "Our domestic relationship with BioHorizons has been very successful and we are pleased to be able to expand this relationship overseas. We believe our bone regeneration products are the perfect solution for the new bone grafting procedures being developed to replace missing or extracted teeth with dental implants or as support for dentures, crowns and bridges."

BioHorizons is a leading oral reconstructive device company at the forefront of digital dentistry. The company has a broad product offering, including surgical planning software, regenerative products, dental implants, CAD/CAM and traditional dental restorations. BioHorizons has a direct sales force in the U.S., Canada, Germany, Spain, United Kingdom, Australia, Mexico, and Chile. Products are distributed in the rest of the world via a network of independent distributors.

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing OsteoBiologic solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech or this press release, please go to Osteotech's website at http://www.osteotech.com.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements (as such are defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company's ability to develop and introduce new products, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. Certain of these factors are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. All information in this press release is as of April 30, 2008 and the Company does not intend to update this information.


'/>"/>
SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Osteotech Signs Agreement To Distribute Harvest Technologies BMAC(TM) System
2. Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09
3. Osteotech Announces Third Quarter Earnings Release and Conference Call Schedule
4. Osteotech Completes Tissue Supply Agreement With LifeNet Health
5. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
6. ISTA Pharmaceuticals Engages Cowen as Financial Advisor
7. Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
8. Availity Engages Prematics to Deploy Electronic Prescribing Solution
9. Availity Engages Prematics to Deploy Electronic Prescribing
10. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
11. Roche Engages in Four Additional AIDS Technology Transfers to Strengthen Local Manufacturing in Worlds Poorest Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... Alaska (PRWEB) , ... May 22, 2017 , ... Galena, ... near the Arctic Circle made big headlines when it was targeted to build a ... Energy in Bush Alaska,” former city manager Marvin L. Yoder describes the journey to ...
(Date:5/22/2017)... ... May 22, 2017 , ... WeightZone Factor a ... WeightZone Factor members to track their exercise patterns, monitor behavioral changes, employ biometric ... on their mobile phones. It also provides social networks for members with similar ...
(Date:5/21/2017)... ... , ... Chris Cornell, 52, was found dead on the night of Wednesday, May 17, 2017. ... singers in the rock industry would take his own life, but the extremely talented and ... illness played a role in the death of Chris Cornell . , Depression and ...
(Date:5/21/2017)... ID (PRWEB) , ... May 20, 2017 , ... ... financial integration systems between ABC Financial Services and financial systems. , ... link or exported files that are electronically processed through GetLinked into their club’s ...
(Date:5/21/2017)... WINTER PARK, FL (PRWEB) , ... May 20, 2017 , ... ... now sell it, find it, review it, and share its attributes like never before. ... online dispensary directory to connect cannabis enthusiasts to stores, strains, products – and for ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... and SAN DIEGO , May ... Gynecologists (ACOG) 2017 Annual Clinical and Scientific Meeting— OBP ... illuminating medical devices, today announced the launch of a ... OfficeSPEC and ER-SPEC vaginal specula. ... of extra-small and extra-large sizes makes OBP Medical,s line ...
(Date:5/3/2017)... , May 3, 2017  Kalorama Information notes ... nine percent next year and this is projected ... hematopoietic stem cell (HSCT) or bone marrow transplants ... technologies are well-suited for this task. This according ... publisher Kalorama Information. The various PCR-based methodologies, Sanger ...
(Date:5/2/2017)...  CIVCO Radiotherapy, the leading provider of high ... Nat Geissel has been named president. ... has served as vice president of marketing and ... manager, and most recently, executive vice president and ... of what CIVCO Radiotherapy and its predecessors have ...
Breaking Medicine Technology: